ABBVIE
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 2013-01-01
- Employees
- -
- Market Cap
- $346B
- Website
- http://www.abbvie.com
A Phase 1/2 Study Evaluating ABT-751 in Combination With Alimta in Advanced Non-Small Cell Lung Cancer
- Conditions
- Lung CancerNSCLCNon-Small-Cell Lung Cancer
- Interventions
- First Posted Date
- 2006-02-28
- Last Posted Date
- 2013-01-31
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 165
- Registration Number
- NCT00297089
- Locations
- 🇺🇸
Site Reference ID/Investigator# 3358, Fayetteville, Arkansas, United States
🇺🇸Site Reference ID/Investigator# 4102, Hot Springs, Arkansas, United States
🇺🇸Site Reference ID/Investigator# 2127, Greenbrae, California, United States
Efficacy and Safety of ABT-874 in Subjects With Moderate to Severe Chronic Plaque Psoriasis
- Conditions
- Psoriasis
- Interventions
- Drug: Anti IL-12 monoclonal antibody/ABT-874Drug: placebo
- First Posted Date
- 2006-02-16
- Last Posted Date
- 2013-01-18
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 180
- Registration Number
- NCT00292396
- Locations
- 🇺🇸
Site Reference ID/Investigator# 3351, San Diego, California, United States
🇺🇸Site Reference ID/Investigator# 3347, Alpharetta, Georgia, United States
🇺🇸Site Reference ID/Investigator# 3348, Skokie, Illinois, United States
Safety of Lopinavir/Ritonavir (Kaletra) in HIV/HCV Co-infected Subjects vs Baseline Liver Biopsy Metavir Score
- First Posted Date
- 2005-10-10
- Last Posted Date
- 2013-01-03
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 86
- Registration Number
- NCT00234975
- Locations
- 🇵🇷
Site Reference ID/Investigator# 4118, Bayamon, Puerto Rico
🇵🇷Site Reference ID/Investigator# 4119, Bayamon, Puerto Rico
🇵🇷Site Reference ID/Investigator# 6298, Juana Diaz, Puerto Rico
Efficacy and Safety of Adalimumab and Methotrexate (MTX) Versus MTX Monotherapy in Subjects With Early Rheumatoid Arthritis
- Conditions
- Early Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2013-07-12
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 799
- Registration Number
- NCT00195663
- Locations
- 🇺🇸
Site Reference ID/Investigator# 322, Scottsdale, Arizona, United States
🇺🇸Site Ref # / Investigator 95957, La Jolla, California, United States
🇺🇸Site Reference ID/Investigator# 429, La Jolla, California, United States
Long-term Study of Duodopa (Levodopa/Carbidopa) in Advanced Parkinson's: Health Outcomes & Net Economic Impact
- Conditions
- Advanced Idiopathic Parkinson's Disease
- Interventions
- Drug: Levodopa-carbidopa intestinal gel (LCIG)Device: CADD-Legacy® 1400 ambulatory infusion pumpDevice: percutaneous endoscopic gastrostomy tube (PEG tube)Device: jejunal extension tube (J-tube)
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2016-07-18
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 77
- Registration Number
- NCT00141518
Safety and Effectiveness of Two Doses of ABT-874 as Compared to Placebo in Subjects With Multiple Sclerosis (MS)
- Conditions
- Multiple Sclerosis
- Interventions
- Drug: ABT-874/Human monoclonal antibody against IL-12Drug: Placebo
- First Posted Date
- 2004-07-09
- Last Posted Date
- 2013-01-04
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 215
- Registration Number
- NCT00086671
- Locations
- 🇺🇸
Site Reference ID/Investigator# 107, Phoenix, Arizona, United States
🇺🇸Site Reference ID/Investigator# 163, Sun City, Arizona, United States
🇺🇸Site Reference ID/Investigator# 156, Little Rock, Arkansas, United States